|
|
|
|
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C.
20549
FORM 8-K/A
(AMENDMENT NO. 1)
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
|
Date of report (Date of earliest event reported): December 8, 2006 |
||
|
|
||
|
GENTA INCORPORATED |
||
|
(Exact Name of Registrant |
||
|
|
||
|
|
Delaware |
|
|
|
(State or Other Jurisdiction of Incorporation) |
|
|
|
||
|
0-19635 |
|
33-0326866 |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
|
|
||
|
200 Connell Drive Berkeley Heights, NJ |
|
07922 |
|
(Address of Principal Executive Offices) |
|
(Zip Code) |
|
|
||
|
|
(908) 286-9800 |
|
|
(Registrant’s Telephone Number, Including Area Code) |
||
|
|
||
|
(Former Name or Former Address, if Changed Since Last Report) |
||
|
|
||
|
|
||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)
Pre -commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d
-2(b))
Pre -commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
|
|
|
Explanatory Note.
This Amendment No. 1 on Form 8-K/A amends the Current Report on Form 8-K of Genta Incorporated (the “Company”), filed with the Securities and Exchange Commission on December 8, 2006. This Amendment No. 1 eliminates the unnecessary “Section 18 Legend”, which was inadvertently included in the previously filed report.
Item 8.01 Other Events.
On December 8, 2006, Genta Incorporated (NASDAQ: GNTA) issued a press release announcing that the Company has been notified of preliminary results from a randomized Phase 3 trial of chemotherapy with or without Genasense® (oblimersen sodium) Injection that was conducted in older, previously untreated patients with acute myelogenous leukemia. According to the analysis conducted by the Cancer and Leukemia Group B, the trial failed to meet its primary endpoint of overall survival.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit Number |
Description |
|
|
99.1 |
Press Release of the Company dated December 8, 2006 |
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
GENTA INCORPORATED |
|||
|
Date: |
December 11, 2006 |
|
By: |
/s/ RICHARD J. MORAN |
|
|
|
|
|
|
Name: |
Richard J. Moran |
|
|
|
|
|
Title: |
Senior Vice President, Chief Financial Officer and Corporate Secretary |
EXHIBIT INDEX
|
Exhibit |
Description |
Sequentially |
|
99.1 |
Press Release of the Company dated December 8, 2006
|
|